{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:11:35Z","timestamp":1793211095623,"version":"4.5.0"},"reference-count":159,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul Cancro, Milan, Italy","award":["AIRC IG 2020\u2014ID. 24566"],"award-info":[{"award-number":["AIRC IG 2020\u2014ID. 24566"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro, Milan, Italy","award":["MANU\/DE\/2023"],"award-info":[{"award-number":["MANU\/DE\/2023"]}]},{"name":"Associazione Italiana per la Ricerca sul Cancro, Milan, Italy","award":["CRP\/MDA22-01"],"award-info":[{"award-number":["CRP\/MDA22-01"]}]},{"name":"Macedonian Academy of Sciences and Arts, Skopje, North Macedonia","award":["AIRC IG 2020\u2014ID. 24566"],"award-info":[{"award-number":["AIRC IG 2020\u2014ID. 24566"]}]},{"name":"Macedonian Academy of Sciences and Arts, Skopje, North Macedonia","award":["MANU\/DE\/2023"],"award-info":[{"award-number":["MANU\/DE\/2023"]}]},{"name":"Macedonian Academy of Sciences and Arts, Skopje, North Macedonia","award":["CRP\/MDA22-01"],"award-info":[{"award-number":["CRP\/MDA22-01"]}]},{"name":"ICGEB, Trieste, Italy","award":["AIRC IG 2020\u2014ID. 24566"],"award-info":[{"award-number":["AIRC IG 2020\u2014ID. 24566"]}]},{"name":"ICGEB, Trieste, Italy","award":["MANU\/DE\/2023"],"award-info":[{"award-number":["MANU\/DE\/2023"]}]},{"name":"ICGEB, Trieste, Italy","award":["CRP\/MDA22-01"],"award-info":[{"award-number":["CRP\/MDA22-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy and a heterogeneous entity comprised of several biologically distinct subtypes. Recently, novel genetic classifications of DLBCL have been resolved based on common mutational patterns indicative of distinct pathways of transformation. However, the complicated and costly nature of the novel classifiers has precluded their inclusion into routine practice. In view of this, the status of the TP53 gene, which is mutated or deleted in 20\u201330% of the cases, has emerged as an important prognostic factor for DLBCL patients, setting itself apart from other predictors. TP53 genetic lesions are particularly enriched in a genetic subtype of DLBCL that shares genomic features with Richter Syndrome, highlighting the possibility of a subset of DLBCL arising from the transformation of an occult chronic lymphocytic leukemia-like malignancy, such as monoclonal B-cell lymphocytosis. Patients with TP53-mutated DLBCL, including those with Richter Syndrome, have a particularly poor prognosis and display inferior responses to standard chemoimmunotherapy regimens. The data presented in this manuscript argue for the need for improved and more practical risk-stratification models for patients with DLBCL and show the potential for the use of TP53 mutational status for prognostication and, in prospect, treatment stratification in DLBCL.<\/jats:p>","DOI":"10.3390\/cancers16122170","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:05:17Z","timestamp":1717747517000},"page":"2170","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-5187","authenticated-orcid":false,"given":"Ivan","family":"Negara","sequence":"first","affiliation":[{"name":"Molecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy"},{"name":"Department of Internal Medicine, Hematology, \u201cNicolae Testemitanu\u201d State University of Medicine and Pharmacy, 2004 Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-1519","authenticated-orcid":false,"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanda","family":"Buruiana","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology, \u201cNicolae Testemitanu\u201d State University of Medicine and Pharmacy, 2004 Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-5462","authenticated-orcid":false,"given":"Dimitar G.","family":"Efremov","sequence":"additional","affiliation":[{"name":"Molecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy"},{"name":"Macedonian Academy of Sciences and Arts, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","article-title":"Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: Implications for the development of novel therapeutic strategies","volume":"10","author":"Elstrom","year":"2010","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17474086.2017.1356714","article-title":"Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?","volume":"10","author":"Ansuinelli","year":"2017","journal-title":"Expert. Rev. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma\u2014Treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.2020005857","article-title":"The dangers of d\u00e9j\u00e0 vu: Memory B cells as the cells of origin of ABC-DLBCLs","volume":"136","author":"Venturutti","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","article-title":"Tonic B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Efremov, D.G., Turkalj, S., and Laurenti, L. (2020). Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. Cancers, 12.","DOI":"10.3390\/cancers12061396"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e20230941","DOI":"10.1084\/jem.20230941","article-title":"Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL","volume":"221","author":"Eken","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2021012052","article-title":"Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior","volume":"138","author":"Chiodin","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41375-019-0442-8","article-title":"Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative\/BCL-2-positive diffuse large B-cell lymphoma","volume":"33","author":"Sasi","year":"2019","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical Impact of the Cell-of-Origin Classification and the MYC\/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated within Prospective Clinical Trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u201cdouble hit\u201d diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: When and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2015.01.009","article-title":"MYC alterations in diffuse large B-cell lymphomas","volume":"52","author":"Karube","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study","volume":"96","author":"Laude","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1047115","DOI":"10.3389\/fimmu.2022.1047115","article-title":"High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/bloodadvances.2020001727","article-title":"Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma","volume":"4","author":"Meriranta","year":"2020","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.15619","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: Findings from the UK\u2019s population-based Haematological Malignancy Research Network","volume":"185","author":"Painter","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17132","article-title":"Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL)","volume":"192","author":"Runge","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00277-017-3094-7","article-title":"Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations","volume":"96","author":"Cao","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B-cell lymphoma: Why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","article-title":"Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma","volume":"8","author":"Fang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1002\/ctm2.584","article-title":"Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1\/2 and biomarker study","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","article-title":"Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment","volume":"16","author":"Yu","year":"2019","journal-title":"Cell Mol. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients with ABC-Type Diffuse Large B-Cell Lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood.2022016272","article-title":"Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo","volume":"140","author":"Martines","year":"2022","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.2023021002","article-title":"Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma","volume":"143","author":"Cerchietti","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1541-7786.MCR-14-0387","article-title":"Lymphocyte Invasion in IC10\/Basal-Like Breast Tumors Is Associated with Wild-Type TP53","volume":"13","author":"Quigley","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s13046-019-1403-9","article-title":"IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression","volume":"38","author":"Thiem","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1128\/MCB.01202-08","article-title":"p53 Regulates Toll-Like Receptor 3 Expression and Function in Human Epithelial Cell Lines","volume":"28","author":"Taura","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Menendez, D., Shatz, M., Azzam, K., Garantziotis, S., Fessler, M.B., and Resnick, M.A. (2011). The Toll-Like Receptor Gene Family Is Integrated into Human DNA Damage and p53 Networks. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1001360"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.1619555114","article-title":"Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth","volume":"114","author":"Hashwah","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/s41467-022-33739-2","article-title":"Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape","volume":"13","author":"Mangolini","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bonato, A., Chakraborty, S., Bomben, R., Canarutto, G., Felician, G., Martines, C., Zucchetto, A., Pozzo, F., Vujovikj, M., and Polesel, J. (Leukemia, 2024). NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia, Leukemia, Online ahead of print.","DOI":"10.1038\/s41375-024-02224-8"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/s41598-020-80376-0","article-title":"Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma","volume":"11","author":"Pedrosa","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ivanova, V.-S., Vela, V., Dirnhofer, S., Dobbie, M., Stenner, F., Knoblich, J., Tzankov, A., and Menter, T. (Pathobiology, 2023). Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases, Pathobiology, Online ahead of print.","DOI":"10.1159\/000535938"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Medeiros","year":"2012","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The significance of TP53 in lymphoid malignancies: Mutation prevalence, regulation, prognostic impact and potential as a therapeutic target","volume":"146","author":"Cheung","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/humu.10190","article-title":"TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance","volume":"21","author":"Peller","year":"2003","journal-title":"Hum. Mutat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.leu.2403254","article-title":"Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt\u2019s lymphoma in children","volume":"18","author":"Wilda","year":"2004","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.2020007507","article-title":"Mutational landscape of gray zone lymphoma","volume":"137","author":"Sarkozy","year":"2021","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/cas.14238","article-title":"TP53 alterations in relapsed childhood acute lymphoblastic leukemia","volume":"111","author":"Yu","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Gaidano","year":"1993","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"628807","DOI":"10.3389\/fonc.2021.628807","article-title":"Mutational Profile and Clonal Evolution of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"11","author":"Lee","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","article-title":"The p53 pathway: Positive and negative feedback loops","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/onc.2009.290","article-title":"Transcription activity is required for p53-dependent tumor suppression","volume":"28","author":"Gaidarenko","year":"2009","journal-title":"Oncogene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1038\/sj.onc.1209641","article-title":"Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo","volume":"25","author":"Palacios","year":"2006","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Voropaeva, E.N., Pospelova, T.I., Voevoda, M.I., Maksimov, V.N., Orlov, Y.L., and Seregina, O.B. (2019). Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-019-0484-9"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Porpaczy, E., Wohlfarth, P., K\u00f6nigsbr\u00fcgge, O., Rabitsch, W., Skrabs, C., Staber, P., Worel, N., M\u00fcllauer, L., Simonitsch-Klupp, I., and Kornauth, C. (2021). Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers, 13.","DOI":"10.3390\/cancers13225592"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cdd.2013.17","article-title":"Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis","volume":"20","author":"Hanel","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.18632\/oncotarget.24656","article-title":"TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: Prognostic markers identified via exome analysis of cases with extreme prognosis","volume":"9","author":"Dobashi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/ijc.30838","article-title":"TP53 mutation and survival in aggressive B cell lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.2147\/CMAR.S269624","article-title":"Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients","volume":"12","author":"Qin","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_102","first-page":"89","article-title":"[Clinical Significance of P53, C-MYC and BCL-6 Abnormality in Patients with Diffuse Large B Cell Lymphoma]","volume":"24","author":"Chai","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_103","first-page":"893","article-title":"Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"19","author":"Qin","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/bjh.17971","article-title":"Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial","volume":"196","author":"Chiappella","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/ijc.33049","article-title":"Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup","volume":"147","author":"Jiang","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: Impact of TP53 mutations on clinical outcome","volume":"107","author":"Dodero","year":"2022","journal-title":"Haematologica"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/jha2.517","article-title":"Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial","volume":"3","author":"Zhu","year":"2022","journal-title":"eJHaem"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/mc.23476","article-title":"Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing","volume":"62","author":"Hou","year":"2023","journal-title":"Mol. Carcinog."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdf185","article-title":"p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas","volume":"13","author":"Leroy","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2008.06.022","article-title":"TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype","volume":"33","author":"Zainuddin","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199708213370804","article-title":"Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma","volume":"337","author":"Ichikawa","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"83294","DOI":"10.18632\/oncotarget.13065","article-title":"Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1182\/bloodadvances.2023011384","article-title":"TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era","volume":"7","author":"Landsburg","year":"2023","journal-title":"Blood Adv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-022-00617-5","article-title":"Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms","volume":"12","author":"Albitar","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1158\/1078-0432.CCR-20-2378","article-title":"Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP","volume":"27","author":"Song","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"16734","DOI":"10.1002\/cam4.6295","article-title":"A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET\/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Robrecht","year":"2021","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/hematology.2022000345","article-title":"Treatment of Richter\u2019s syndrome","volume":"2022","author":"Thompson","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2019.239947","article-title":"Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: A multi-center study","volume":"106","author":"Leeksma","year":"2021","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1182\/bloodadvances.2023010753","article-title":"Characteristics and outcomes of patients with CLL and CDKN2A\/B deletion by fluorescence in situ hybridization","volume":"7","author":"Teierle","year":"2023","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Hergalant","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2009.014100","article-title":"Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type","volume":"95","author":"Tierens","year":"2010","journal-title":"Haematologica"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2015.126656","article-title":"Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell","volume":"100","author":"Malecka","year":"2015","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_136","first-page":"11","article-title":"Richter syndrome: Novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: A GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood.2023022048","article-title":"Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: No ordinary subgroup analysis","volume":"142","author":"Cliff","year":"2023","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential Efficacy from the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study with a 5-Year Follow-Up","volume":"41","author":"Davies","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.22.00597","article-title":"Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients with Newly Diagnosed Large B-Cell Lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1182\/bloodadvances.2022009467","article-title":"Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma","volume":"7","author":"Burack","year":"2023","journal-title":"Blood Adv."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hon.2368","article-title":"Low-dose radiotherapy in diffuse large B-cell lymphoma","volume":"35","author":"Furlan","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2007-01-067579","article-title":"In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma","volume":"110","author":"Knoops","year":"2007","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: One protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study","volume":"10","author":"Goldberg","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine after Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1182\/blood-2022-164434","article-title":"The DLBCL Axis of Low TNFRSF10B Expression, TP53 Loss, and a Cold Immune Microenvironment May be Addressed by the Synergistic Combination of Eprenetapopt and Idasnutlin","volume":"140","author":"Rutz","year":"2022","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): Analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1097\/HS9.0000000000000870","article-title":"Zanubrutinib, Alone and in Combination with Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Hemasphere"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2022-157058","article-title":"Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1\/2 BRUIN Study","volume":"140","author":"Wierda","year":"2022","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hon.3164_343","article-title":"Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome","volume":"41","author":"Davids","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated with CD19-Chimeric Antigen Receptor T-Cell Therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e2123227119","DOI":"10.1073\/pnas.2123227119","article-title":"Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia","volume":"119","author":"Kogan","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2170\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:55:17Z","timestamp":1760108117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":159,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16122170"],"URL":"https:\/\/doi.org\/10.3390\/cancers16122170","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}